Piramal Pharma Limited — Important, 28-01-2025: Financial Result Updates

**Consolidated Financial Results**

Piramal Pharma Limited reported total income of ₹2,216.35 Crores for the quarter ended December 31, 2024, reflecting a year-over-year growth of approximately 9.7% from ₹2,020.08 Crores in the same period last year. This boost can be attributed to increased demand for pharmaceutical products, partially offset by the ongoing market challenges faced by its subsidiaries.

The company registered a profit before tax of ₹49.75 Crores, compared to ₹37.68 Crores in Q3 2023, while net profit after tax stood at ₹3.68 Crores, showing an improvement from a loss of ₹10.11 Crores in the corresponding quarter last year. The Earnings Per Share (EPS) for the period is reported at ₹0.03.

Operational costs increased 9% year-on-year to ₹2,166.60 Crores, with employee benefits and material costs being notable contributors. Employee benefits expense was stable at around ₹556.24 Crores, reflecting effective cost management strategies despite overall rising costs.

The balance sheet remains sturdy, with total assets reflecting continued operational capabilities, although net profit margins indicate a cautious outlook.

**Strategic Position and Outlook**

Piramal is focusing on consolidating its market position while navigating turbulent market conditions, particularly in its critical care segments. The initiation of insolvency proceedings related to suppliers is a risk factor, potentially impacting costs and sales.

**Investor Insight**

Given the improvement in profitability and operational management despite challenges, a **hold** position may be prudent for retail investors, watching for further expansion and demand stabilization in upcoming quarters.